|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2001-5-14
|
|
pubmed:abstractText |
The hypotensive effect of imidazoline-like drugs, such as clonidine, was first attributed to the exclusive stimulation of central alpha2-adrenoceptors (alpha2ARs). However, a body of evidence suggests that non-adrenergic mechanisms may also account for this hypotension. This work aims (i) to check whether imidazoline-like drugs with no alpha2-adrenergic agonist activity may alter blood pressure (BP) and (ii) to seek a possible interaction between such a drug and an alpha2ARs agonist alpha-methylnoradrenaline (alpha-MNA). We selected S23515 and S23757, two imidazoline-like drugs with negligible affinities and activities at alpha2ARs but with high affinities for non-adrenergic imidazoline binding sites (IBS). S23515 decreased BP dose-dependently (-27+/-5% maximal effect) when administered intracisternally (i.c.) to anaesthetized rabbits. The hypotension induced by S23515 (100 microg kg(-1) i.c.) was prevented by S23757 (1 mg kg(-1) i.c.) and efaroxan (10 microg kg(-1) i.c.), while these compounds, devoid of haemodynamic action by themselves, did not alter the hypotensive effect of alpha-MNA (3 and 30 microg kg(-1) i.c.). Moreover, the alpha2ARs antagonist rauwolscine (3 microg kg(-1) i.c.) did not prevent the effect of S23515. Finally, whilst 3 microg kg(-1) of S23515 or 0.5 microg kg(-1) of alpha-MNA had weak hypotensive effects, the sequential i.c. administration of these two drugs induced a marked hypotension (-23+/-2%). These results indicate that an imidazoline-like drug with no alpha2-adrenergic properties lowers BP and interacts synergistically with an alpha(ARs agonist.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-10799665,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-10825384,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-1355733,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-2158551,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-2390682,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-2690423,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-2721559,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-2891039,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-3007903,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-374097,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-4146793,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-6111465,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-6146707,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-7215437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-8306110,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-8377842,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-8387366,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-8670421,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-8818924,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-8981563,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-9208095,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-9374796,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11350862-9605427
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0007-1188
|
|
pubmed:author |
pubmed-author:BousquetPP,
pubmed-author:BoutinJJ,
pubmed-author:BrubanVV,
pubmed-author:DontenwillMM,
pubmed-author:FeldmanJJ,
pubmed-author:GrenetCC,
pubmed-author:JarryCC,
pubmed-author:PayardMM,
pubmed-author:PfeifferBB,
pubmed-author:RenardPP,
pubmed-author:ScalbertEE,
pubmed-author:SchanoPP,
pubmed-author:VanhouttePP
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
133
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
261-6
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11350862-Animals,
pubmed-meshheading:11350862-Antihypertensive Agents,
pubmed-meshheading:11350862-Blood Pressure,
pubmed-meshheading:11350862-Cattle,
pubmed-meshheading:11350862-Cisterna Magna,
pubmed-meshheading:11350862-Cyclic AMP,
pubmed-meshheading:11350862-Guanosine 5'-O-(3-Thiotriphosphate),
pubmed-meshheading:11350862-HT29 Cells,
pubmed-meshheading:11350862-Hemodynamics,
pubmed-meshheading:11350862-Humans,
pubmed-meshheading:11350862-Imidazoles,
pubmed-meshheading:11350862-Injections,
pubmed-meshheading:11350862-Male,
pubmed-meshheading:11350862-Oxazoles,
pubmed-meshheading:11350862-Rabbits,
pubmed-meshheading:11350862-Radioligand Assay,
pubmed-meshheading:11350862-Receptors, Adrenergic, alpha
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Respective contributions of alpha-adrenergic and non-adrenergic mechanisms in the hypotensive effect of imidazoline-like drugs.
|
|
pubmed:affiliation |
Laboratoire de Neurobiologie et Pharmacologie Cardiovasculaire, Faculté de Médecine, Université Louis Pasteur, 11 rue Humann, 67000 Strasbourg, France.
|
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, Non-U.S. Gov't
|
